As 2025 comes to a close, I'm reflecting on the outstanding people and teams I've been lucky to work with at Dana-Farber to advance lung cancer care in the clinic and in research Look forward to a bright 2026! @danafarber.bsky.social @danafarbernews.bsky.social #lcsm

Great to share lung cancer research updates with colleagues and friends at the 2025 IASLC NACLC meeting Thank you to chairs Drs. Bestvina, Marrone, Rengan and Gillaspie for organizing an energizing and fun conference @iaslc.bsky.social @danafarber.bsky.social #NACLC25

1/ In JCO: PO, we describe the presentation of NUT carcinoma- it almost always presents as a poorly differentiated/ squamous lung, head and neck cancer, with a mean biopsy to diagnosis interval of 7 weeks (!) 🫁 🗣️ doi.org/10.1200/PO-2... #medsky #oncsky #lungcancer @ascocancer.bsky.social 🧵A thread:

🚨 >50% of ID fellowships went unfilled—just as the need is surging. Currently on ID consults and seeing unprecedented volumes and an increasingly immunocompromised population at risk for life-threatening infections. I’m worried we’re heading toward fewer specialists when we need them most.

Alexander Drilon, Jolanta Grembecka, Jessica Jiyeong Lin, and Jia Luo will discuss "Translating Discoveries Toward New Therapies" in a plenary session at the AACR Conference on Fusion-Positive Cancers (January 13-15, 2026; Philadelphia). Learn more: buff.ly/3jO4l4j #AACRfusion26 @jia-luo.bsky.social

@stolaney1.bsky.social addresses a full house during the #ESMO25 presidential discussion on Reshaping Density – Transforming Outcomes in High-Risk HER2+ Breast Cancer.

Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study. Press release ➡️bit.ly/47oV0hd

What a great throwback! Brings me back to middle school computer lab when - as the cool kids - we were using this little known search called "google" on our bright boxy blue iMacs when the standard at the time was Ask Jeeves

A deep dive into the destruction of US cancer research by @jonathanmahler.bsky.social “It’s an absolutely unmitigated disaster,” a former top official at NIH told him. “It will take decades to recover from this, if we ever do.” Gift link: nyti.ms/48iH3Cr

What a fantastic IASLC WCLC25! Congrats to star resident (onc-to-be!) Dr Huang & We had a superb global multi-D discussion on ground glass/semisolid lung nodules - packed room in our last session of the day! TY chairs Drs Naidoo Opitz Malapelle & Noemi - feeling inspired 🙏 @iaslc.bsky.social

For us ID doctors, the CDC has been a rock. Data, guidelines, surveillance, travel advice -- all there, vetted by experts, referenced, reliable. Perfect? No. But watching its dismantling now breaks my heart. Some thoughts: blogs.jwatch.org/hiv-id-obser...

🩻 Look forward to our interactive multidisciplinary lung nodules session @ IASLC WCLC 2025 meeting next week, September 6-9 in Barcelona It's been fantastic to plan our program with this group of experts spanning the 🗺️, meeting 6am (PT) - 11pm (AEST)! wclc.iaslc.org #lcsm @iaslc.bsky.social #WCLC25

New report from AAMC about clinical trials, other grants, and training www.aamc.org/about-us/mis...

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology. Learn more: bit.ly/45wiiQ6

Fantastic to interview Dr. William Pao about his book "Breakthrough" with Dr. Jänne So inspiring for us to hear stories about resiliency and learning from failure in research to develop transformational medicines Special thanks to Sitara & the Chen-Huang Center #lcsm @danafarber.bsky.social

Excited to host drug developer extraordinaire Dr. William Pao at Dana-Farber Dr. Jänne and I will interview Dr. Pao tomorrow (Tuesday, August 12) about his book, Breakthrough, "a triumphant read about overcoming disease" www.simonandschuster.com/books/Breakt... @danafarbernews.bsky.social

🩺 In NEJM, our interactive case on a common CC - evaluation of a patient with new pulmonary symptoms www.nejm.org/doi/full/10.... Congrats to star fellow Dr Joanne I. Hsu for leading & wonderful to learn from expert multi-D colleagues @anandvaidya17.bsky.social @harvardmed.bsky.social @nejm.org

Celebrating endings and new beginnings - it has been fantastic to have Dr Paoloni on our research team during his awarded American-Italian Cancer Foundation Research Fellowship grant! @danafarber.bsky.social @danafarbernews.bsky.social #lcsm

New STAT story about multi-year funding. www.statnews.com/2025/07/29/n...

1/ In Clinical Cancer Research, we examined underdiagnosis of NUT carcinoma, an aggressive squamous lung, head and neck cancer, and found >75% are missed on standard of care testing (DNA panel NGS) 🫁 🗣️ doi.org/10.1158/1078... #medsky #oncsky #meded #lcsm #lungcancer @theaacr.bsky.social 🧵A thread:

🌟 Some great colleagues, including Dr Julia Rotow, and I will be discussing the latest practice changing data in oncology @ Best of ASCO Boston July 26-27! Program and registration horizoncme.com/best-of-asco... #oncsky @ascocancer.bsky.social @danafarbernews.bsky.social @danafarber.bsky.social

Encouraging news from the US FDA - a fast track designation - for our patients with NUT carcinoma! It's been incredible team science from the preclinical, to the iterative FIH translation, to our ongoing NIH-funded NCI CTEP/ETCTN clinical trial #oncsky #lcsm

I am seeking a postdoc for my group at UCLA. We work at the intersection of population genetics x microbiome (garud.eeb.ucla.edu). If interested, please message me!

These members of the NIH Council of Councils are voicing serious concerns about NIH grant terminations, restructure, and budget cuts go.nature.com/46Vr8t2

Outstanding commencement speech by Sandra Oh fit for these times on living with discomfort. Well worth the watch. youtu.be/P7TYeFy0JtA?...

🗺️ 🫁 Thrilled to work with and learn from this multi-D international panel of lung cancer experts We’ve got a fantastic interactive discussion on pulmonary nodules planned - Tues Sept 9 @ IASLC #WCLC25 in Barcelona Join us! / Register: wclc.iaslc.org @iaslc.bsky.social #lcsm #medsky

Celebrating a win - when a fantastic CRC in your group achieves their dream of going to medical school!

Republicans are poised to pass the biggest cuts in health coverage ever. @nytopinion.nytimes.com www.nytimes.com/2025/07/01/o...

On Juneteenth, we celebrate freedom and recommit ourselves to the work that remains undone. We remember that even in the darkest hours, there is cause to hope for tomorrow’s light.

I’ve been in academic medicine for 45 years. This is the first time I’m seeing a perfect storm, as proposed federal funding cuts threaten our ability to provide patient care, train the next generation of doctors, and conduct life-saving research. More from my conversation with @cnn.com last week.

Every machine in a Hospital that diagnoses your body without cutting you open is based on a principle of Physics, discovered by a Physicist who had no interest in Medicine. If you think the world doesn’t need Basic Science, or that somehow Science has failed you, think again.

“The university is totally keeping us on life support,” said Dr. Daniela Matei, a Northwestern oncologist. “The big question is for how long they can do this.” www.wsj.com/us-news/educ...

Grateful to have grown up with family, teachers, and (girl)friends who encouraged and celebrated math literacy Tangentially, it's crazy how it's acceptable to say "I'm bad at math" but not "I'm bad at writing" www.nature.com/articles/d41...

This NYT visualization shows just a fraction of the growing instability in NIH funding. For the most current—and self-reported—data, bookmark grant-watch.us 👀 (Oh, and they’ve been tracking NSF grants too🙏)

Congratulations to my colleague Mark Kris on his Giant of Cancer Care award from @onclive.bsky.social at #ASCO25 @mskdeptofmed.bsky.social

Great to meet friends and collaborators at #ASCO25 Look forward to discussing some of these practice changing results in treating lung cancers!

@stolaney1.bsky.social ‬, MD, MPH, unveils primary results from the phase 3 ASCENT-04/KEYNOTE-D19 study, comparing sacituzumab govitecan + pembrolizumab to chemo + pembrolizumab in untreated PD-L1 positive advanced TNBC. #ASCO25

David Barbie, MD, presents insights from the phase 3 ADRIATIC trial, examining clinical and molecular traits of early progressors and long-term survivors using durvalumab vs placebo after chemoradiotherapy in limited-stage small-cell lung cancer. #ASCO25

Kartik Sehgal, MD, presents initial findings from a phase 1 study on the combination of sigvotatug vedotin, an investigational IB6-targeted antibody-drug conjugate, with pembrolizumab. #ASCO25

David Liu @harvard.edu beautifully articulates the criticality of basic science funding for developing revolutionary therapeutics like life-saving base editors 👏 youtu.be/8YhJM6zxYDw?...

Wonderful story about a great addition to the McCormick Conference Center where our annual @ascocancer.bsky.social American Society for Clinical Oncology meeting takes place. 🦅 Look forward to checking this out next week at ASCO 2025! www.nytimes.com/2025/05/20/c... #oncsky

🌟 Some great colleagues, including Dr Julia Rotow, and I will be discussing the latest practice changing data in oncology @ Best of ASCO Boston July 26-27! Program and registration horizoncme.com/best-of-asco... #oncsky @ascocancer.bsky.social @danafarbernews.bsky.social @danafarber.bsky.social

wow — in all of this, it still surprises me how rarely biomedical research is explicitly and dramatically linked to why we do it despite being incredibly hard because people’s lives are at stake everyone’s life is at stake

Congrats to @danafarber.bsky.social’s Brian Wolpin, MD, MPH, a 2025 Giants of Cancer Care by @onclive.bsky.social. Dr. Wolpin is recognized for his remarkable achievements in #gastrointestinal and #pancreatic cancer research and clinical practice. ➡️ bit.ly/3RTq7ZS

Thanks AACR for bringing together people around the world dedicated to fighting cancer. #aacr25

What can you do? Make noise. The ask is “Leave NIH funding at last year’s (FY24) level. No DOGE cuts. No recission to codify cuts. Hands off NIH.” If they are going to vote to cut cancer research, lets make that clear. donmoynihan.substack.com/p/the-nih-bu...

🌟 Outstanding AACR Scientific Achievement Award lecture by Dr Alice Shaw on decades of research led by her and many others on developing effective targeted medicines for lung cancers #AACR25 @theaacr.bsky.social @danafarber.bsky.social #lcsm